NCT07072195

A Study of AMC6156 in People With Sarcopenia

A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of AMC6156 in Patients With Sarcopenia

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Animuscure Inc. · Industry
• Sex: All
• Age: 65 Years
• Healthy volunteers: Not accepted

Summary

This clinical trial aims to find out whether AMC6156 can improve physical function and is safe in older adults with sarcopenia. Participants will take AMC6156 or a placebo daily for 12 weeks, and their movement, strength, and safety will be regularly monitored through tests and checkups.

Conditions

• Sarcopenia in Elderly
• Sarcopenia

Interventions

Type	Name	Description
DRUG	AMC6156 0.1mg	Oral administration of AMC6156 in tablet form at a dose of 0.1 mg once daily for 12 weeks.
DRUG	AMC6156 0.3mg	Oral administration of AMC6156 in tablet form at a dose of 0.3 mg once daily for 12 weeks.
DRUG	AMC6156 1.0mg	Oral administration of AMC6156 in tablet form at a dose of 1.0 mg once daily for 12 weeks.
DRUG	Placebo	Oral administration of placebo tablets matching AMC6156 in appearance, once daily for 12 weeks.

Timeline

• Start date: 2025-07-01
• Primary completion: 2026-03-01
• Completion: 2026-06-01
• First posted: 2025-07-18
• Last updated: 2025-07-29

Locations

4 sites across 1 country: South Korea